cyc 202 has been researched along with gw 2580 in 4 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (gw 2580) | Trials (gw 2580) | Recent Studies (post-2010) (gw 2580) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 48 | 0 | 40 |
| Protein | Taxonomy | cyc 202 (IC50) | gw 2580 (IC50) |
|---|---|---|---|
| Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR | Homo sapiens (human) | 0.038 | |
| Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR | Homo sapiens (human) | 0.038 | |
| Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR | Homo sapiens (human) | 0.038 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.88 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.003 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.1947 | |
| Macrophage colony-stimulating factor 1 receptor | Mus musculus (house mouse) | 0.392 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Russu, WA; Shallal, HM | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
4 other study(ies) available for cyc 202 and gw 2580
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |